PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Cost reduction while RVPH shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
100.00%
Growth of 100.00% while RVPH shows flat gross profit. Bruce Berkowitz would examine quality advantage.
No Data
No Data available this quarter, please select a different quarter.
10.75%
R&D growth less than half of RVPH's 22.81%. David Dodd would verify if efficiency advantage is sustainable.
-21.32%
Both companies reducing G&A. Martin Whitman would check industry cost trends.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.47%
Operating expenses growth less than half of RVPH's 4.09%. David Dodd would verify sustainability.
1.47%
Total costs growth less than half of RVPH's 4.09%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
6.88%
D&A growth while RVPH reduces D&A. John Neff would investigate differences.
-1.39%
EBITDA decline while RVPH shows 100.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-1.47%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-3.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.89%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
2.63%
EPS growth 50-75% of RVPH's 3.85%. Martin Whitman would scrutinize operations.
2.63%
Diluted EPS growth 50-75% of RVPH's 3.85%. Martin Whitman would scrutinize operations.
3.22%
Share count reduction exceeding 1.5x RVPH's 10.63%. David Dodd would verify capital allocation.
3.22%
Diluted share reduction exceeding 1.5x RVPH's 10.64%. David Dodd would verify capital allocation.